AI news
OpenAI acquires Orchestra Bio for its life-sciences research tools
OpenAI says it has acquired Orchestra Bio and plans to combine its drug-development coordination platform and team with Rosalind. The terms were not disclosed. The company describes future agents for tracking studies and decisions; it has not announced a newly available integrated product or clinical result.
Primary source · October 20, 2026
Opens OpenAI in a new tab. Read it there before you rely on the summary above.
Read the original
Free, email only
Unlock the full brief free.
- What to check before you trust this story, written down
- Each verified source, with why it matters and who published it
- A note whenever a source has been withdrawn
- Thirty days of stories to browse, not seven
Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.